Registered title, quoted from ClinicalTrials.gov
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07678957, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Toxicities from prior antitumor therapy have recovered to ≤Grade 1 per NCI-CTCAE v6.0;
Inclusion criterion 9
Received surgery, curative radiotherapy, immunotherapy, or other systemic anti-tumor therapies within 4 weeks prior to the first dose;
Exclusion criterion 1
Prior treatment with anti-HER2 therapy;
Exclusion criterion 3
Prior anthracycline treatment with a cumulative equivalent dose of doxorubicin > 360 mg/m²;
Exclusion criterion 14
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Inclusion criterion 8
Have at least one measurable target lesion per RECIST v1.1 criteria;
Inclusion criterion 7
Diagnosis of another primary malignancy within 5 years prior to the first dose;
Exclusion criterion 9
Positive for human immunodeficiency virus (HIV) antibody, active hepatitis B virus (HBV) infection, liver cirrhosis, or hepatitis C virus (HCV) infection;
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07678957, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form and agree to comply with the protocol requirements;
- Female patients aged ≥18 years and ≤75 years at the time of signing the informed consent form;
- Life expectancy ≥12 weeks;
- Locally recurrent or metastatic breast cancer that is hormone receptor (HR)-positive and HER2-low expressing;
- Provide adequate and recent tumor tissue specimens for central laboratory testing of HER2, HR, and other biomarkers as required;
- Meet the prior treatment requirements as specified in the protocol;
- Have at least one measurable target lesion per RECIST v1.1 criteria;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Toxicities from prior antitumor therapy have recovered to ≤Grade 1 per NCI-CTCAE v6.0;
- Adequate organ function as defined in the protocol;
- For premenopausal women of childbearing potential, a serum pregnancy test must be performed within 7 days prior to the start of treatment and must be negative; patients must not be breastfeeding. All enrolled patients (both male and female) must use adequate and highly effective contraceptive measures throughout the entire treatment period and for 7 months after the last dose of study treatment.
Exclusion Criteria:
- Received surgery, curative radiotherapy, immunotherapy, or other systemic anti-tumor therapies within 4 weeks prior to the first dose;
- Intolerance to the control drug or presence of other contraindications to the control drug;
- Prior treatment with anti-HER2 therapy;
- Prior treatment with an ADC (antibody-drug conjugate) using a camptothecin derivative as the payload;
- History of severe cardiovascular or cerebrovascular disease within 6 months prior to screening;
- Concurrent pulmonary disease resulting in severely impaired lung function;
- History of ILD/interstitial lung disease requiring corticosteroid therapy, etc.;
- QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias;
- Diagnosis of another primary malignancy within 5 years prior to the first dose;
- Uncontrolled hypertension;
- Active central nervous system (CNS) metastases;
- History of severe allergic reactions to any excipient or component of the investigational drug;
- History of autologous or allogeneic stem cell transplantation or organ transplantation;
- Prior anthracycline treatment with a cumulative equivalent dose of doxorubicin > 360 mg/m²;
- Positive for human immunodeficiency virus (HIV) antibody, active hepatitis B virus (HBV) infection, liver cirrhosis, or hepatitis C virus (HCV) infection;
- Occurrence of severe infection within 4 weeks prior to the first dose of the investigational drug;
- Presence of large-volume serous cavity effusion, or serous cavity effusion with significant symptoms;
- Presence of lymphangitic carcinomatosis;
- Receiving systemic corticosteroid therapy at a dose of > 10 mg/day prednisone or equivalent prior to randomization;
- Presence of severe neurological or psychiatric disorders;
- Clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent;
- Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.;
- Planned vaccination or receipt of live vaccine within 28 days prior to the first dose;
- Presence of other severe physical conditions, laboratory abnormalities, or poor compliance, which may increase the risk of participating in the study, interfere with the study results, or render the patient unsuitable for enrollment as judged by the investigator.
Quoted from ClinicalTrials.gov, NCT07678957, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07678957, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.